The validation of new CHD1L inhibitors as a therapeutic strategy for cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer

Published:2024-01 Issue: Volume:170 Page:116037
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Clune Sophia^ORCID,Awolade Paul^ORCID,Zhou Qiong^ORCID,Esquer Hector^ORCID,Matter Brock^ORCID,Kearns Jeffrey T.,Kellett Timothy^ORCID,Akintayo Damilola Caleb,Kompella Uday B.,LaBarbera Daniel V.

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference47 articles.

1. Colorectal cancer statistics, 2023;Siegel;CA: A Cancer J. Clin.,2023

2. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States;Islami;CA: A Cancer J. Clin.,2018

3. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer;Mármol;Int. J. Mol. Sci.,2017

4. Society, A.C., Colorectal Cancer Facts & Figures 2020–2022. Society, A. C., Ed. American Cancer Society: Atlanta, Georgia, 2020.

5. Systemic treatment of colorectal cancer;Wolpin;Gastroenterology,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP